Enjoy complimentary customisation on priority with our Enterprise License!
The Global Interstitial Cystitis (IC) Drugs market size is estimated to grow by USD 369.58 million and the size of the market is estimated to accelerate at a CAGR of 5.9% between 2022 and 2027. Awareness of interstitial cystitis, the advent of gene therapy, advancement in drug, and the increasing approval of drugs is helping fight interstitial cystitis disease. Furthermore, the increasing grants for research on interstitial cystitis are also notably driving market growth. The global interstitial cystitis drugs market is dominated by Johnson and Johnson Inc., Vitaris Inc., Bayer AG, Pfizer Inc., and Sun Pharmaceutical Industries Ltd., among others. The drugs offered by these companies are small molecules and have proven efficacy, which helps these vendors maintain their dominant positions in the market. Vendors in key regions such as North America and Europe are flourishing since many people are dealing with interstitial cystitis disease in these regions. Not only in North America and Europe but also vendors in China and India will also probably lead the interstitial cystitis drugs market in Asia during the forecast period, owing to the development of the healthcare segment.
Technavio has divided the global interstitial cystitis (IC) drugs market into three segments that are Type, Distribution Channel, and Geography.
It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.
To learn more about this report, Download the FREE Report Sample
The type segmentation is divided into two categories that are oral therapy and intravesical therapy. The oral therapy segment was valued at USD 586.82 million in 2017 and continues to grow during the forecast period.
Get a glance at the market contribution of various segments Request a PDF Sample
Pentosan polysulfate sodium (ELMIRON) is the only approved oral medication to repair the lining of the bladder in people with interstitial cystitis (IC). ELMIRON builds and restores the protective coating of the bladder tissue. It can also reduce the swelling of the bladder. Glycosaminoglycan (GAG layer) is composed of a coating of mucus, which protects the bladder wall from bacteria and irritating substances in the urine. There are many off-label oral drugs in the global interstitial cystitis drugs market that can reduce the signs and symptoms of the disease. For instance, in the management of bladder pain, nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and naproxen are widely used. Thus, the demand for oral therapy will drive the growth of the market in focus during the forecast period.
Hotel pharmacies are leading the market during the forecast period. Hospital pharmacies comprise pharmaceuticals that are purchased directly by hospitals from different pharmaceutical companies and used for the treatment of either outpatients or inpatients. The drugs that are found in hospital pharmacies include therapeutic and critical care drugs. The primary aim of hospital pharmacies is to procure, store, and sell medications to patients in hospitals. Hospital pharmaceuticals are administered to individuals during the hospital-enabled treatment period. More hospitals are consolidating into larger healthcare systems, which can include payors, specialty services, outpatient clinics, long-term care facilities, and physician practices. This, in turn, will drive the growth of the market focus during the forecast period.
To know more about segments download the sample reports
North America is estimated to contribute 35% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
For more insights on the market share of various regions Request PDF Sample now!
North America accounted for the largest share of the global IC drugs market, primarily due to the increasing cases of interstitial cystitis in the region. A rise in research funding will also contribute to the growth of the market in the region during the forecast period. Furthermore, the US Food and Drug Administration (FDA) approved ELMIRON and RIMSO-50 for the treatment of interstitial cystitis. These two drugs hold major market shares in this region as they have a better safety profile compared with off-label drugs. Moreover, there are no generics available currently for these approved drugs in the US. Hence, the market in North America will grow with the sales of these approved drugs during the forecast period.
Due to the COVID-19 pandemic in 2020, vendors had to decrease production capacity for certain interstitial cystitis drugs, such as immunosuppressants, because of reduced demand for managing symptoms. Nevertheless, the market bounced back in 2021, as healthcare centers resumed treatment for interstitial cystitis and pharmaceutical companies resumed clinical trials for interstitial cystitis drugs. Additionally, the growth of the regional market will be driven by ongoing developments by vendors operating in the region. As a result of these factors, it is expected that the market will experience positive growth during the forecast period.
There is high competition in the interstitial cystitis drugs market. Among several market players, the organization Allergan stands out among the competitors due to technological innovation and its on-point marketing strategy.
Allergan- The company offers interstitial cystitis (IC) drugs such as Enablex. Also, the company acquires, develops, manufactures, and markets brand-name drugs and medical devices in the areas of medical aesthetics, eye care, the central nervous system, and gastroenterology.
The report also includes detailed analyses of the competitive landscape of the market and information about 15 market vendors, including:
Technavio’s report consists of a holistic analysis of the key development Analysis, development stage, pipeline analysis, FDA approval, market players, their marketing strategies, and powerful innovations to help any client gain a competitive edge.
There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges.
Key Interstitial Cystitis Drugs Market Driver
Bladder pain and lower urinary tract symptoms are common features of interstitial cystitis, a condition that affects many individuals, particularly women. According to a 2018 article by Muhammad Shahid et al. published in the National Center for Biotechnology Information (NCBI), over 3-8 million women and 1-4 million, men are diagnosed with interstitial cystitis annually in the US. Females are more likely to be affected by this condition, which is often linked to comorbidities like allergies, fibromyalgia, and endometriosis. In the UK, around 400,000 individuals have interstitial cystitis, with women accounting for 90% of cases. The Centers for Disease Control and Prevention (CDC) report a prevalence rate of 1.0 to 5.1 people per 100,000 for interstitial cystitis. Consequently, the high prevalence of interstitial cystitis is projected to propel market growth in the forecast period.
Significant Interstitial Cystitis Drugs Market Trend
Increasing approval for drugs is a primary trend in the market. The sole bladder instillation drug approved by the FDA for interstitial cystitis is Dimethyl sulfoxide (DMSO). According to researchers, more than half of patients reported improvement after receiving once-a-week treatments for six weeks. DMSO is occasionally combined with other medications and functions by relaxing the pelvic and bladder muscles to increase bladder capacity. This therapy is becoming more widely recognized as a more effective approach to treating interstitial cystitis. Besides dimethyl sulfoxide, other drugs have been introduced by vendors operating in the market. For example, in April, Kyorin Pharmaceutical Co., Ltd., a wholly-owned subsidiary of KYORIN, launched "Zymso Intravesical Solution" 50% for interstitial cystitis. The rising number of drug launches is expected to propel the market growth during the forecast period.
Major Interstitial Cystitis Drugs Market Challenge
Side effects of available medications is one of the major set back of the market. ELMIRON and RIMSO-50 (dimethyl sulfoxide) are the primary treatment options for interstitial cystitis due to their demonstrated safety and effectiveness in human clinical trials. However, long-term use of these drugs can result in severe side effects, despite their high therapeutic value. ELMIRON may cause nausea, diarrhea, gastric distress, and temporary hair loss, while RIMSO-50 can cause skin reactions, dry skin, headache, diarrhea, constipation, breathing problems, vision problems, and allergic reactions. The administration of RIMSO-50 also results in a garlic-like odor that persists for several hours.
Additionally, many off-label drugs, such as hydroxyzine, heparin, and amitriptyline, are frequently used to manage interstitial cystitis symptoms. Nonetheless, these drugs also have significant side effects. Amitriptyline, for example, can cause drowsiness, constipation, breathing problems, and swelling of the face, lips, tongue, and throat. In January 2022, a lawsuit was filed against Johnson and Johnson (J and J), its subsidiary Janssen Pharmaceuticals, and others in the United States for eye damage caused by the prolonged use of Elmiron to treat interstitial cystitis. Thus, the adverse effects linked to currently available drugs are anticipated to restrict market growth throughout the forecast period.
To know more about drivers, trends, and challenges download the sample reports
Key Interstitial Cystitis Drugs Market Customer Landscape
The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Interstitial Cystitis Drugs Market Customer Landscape
The report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. The market has been segmented by Type (Oral therapy and Intravesical therapy), Distribution Channel (Hospital pharmacies, Retail pharmacies, and Online pharmacies), and Geography (North America, Europe, Asia, and Rest of World (ROW)).
Interstitial Cystitis Drugs Market Scope |
|
Report Coverage |
Details |
Page number |
160 |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 5.9% |
Market growth 2023-2027 |
USD 369.58 million |
Market structure |
Fragmented |
YoY growth 2022-2023(%) |
5.26 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 35% |
Key countries |
US, UK, Germany, Japan, and China |
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled |
Allergan, Amneal Pharmaceuticals Inc., Astellas Pharma Inc., Aurobindo Pharma Ltd., Bayer AG, Cadila Healthcare Ltd., Eli Lilly and Co., Hikma Pharmaceuticals Plc, Intas Pharmaceuticals Ltd., Johnson and Johnson, Kyorin Pharmaceutical Co. Ltd., Mission Pharmacal Co., Perrigo Co. Plc, Pfizer Inc., Purdue Pharma LP, Seikagaku Corp., Sun Pharmaceutical Industries Ltd., Taro Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Market Segmentation by Distribution Channel
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.